Cilofexor CAS No.: 1418274-28-8

Cilofexor, also known as GS-9674, is a novel and selective nonsteroidal farnesoid X receptor (FXR) agonist. This product has been developed by Gilead Sciences, Inc. with the aim of providing a new therapy for patients with chronic liver disease, specifically Non-Alcoholic Steatohepatitis (NASH). NASH is a severe form of fatty liver disease and can lead to cirrhosis, liver cancer and ultimately liver failure.

Cilofexor is a potent oral medication which is available in tablet form. It has been shown to have a good safety profile and has exhibited promising results in clinical trials. Cilofexor is structurally distinct from currently available FXR agonists, making it a unique and valuable addition to the treatment of NASH. It is hoped that Cilofexor will pave the way in the development of new drugs to address the unmet medical need in liver disease.

There are several key features of Cilofexor which make it an attractive product for merchants. Its novel mechanism of action addresses an unmet medical need in a growing market. The prevalence of NASH is increasing rapidly, especially in developed countries where obesity and metabolic disorders are more prevalent. There is a significant and growing demand for effective treatments that can help combat this disease. This presents a tremendous opportunity for merchants looking to supply innovative and effective diagnostic and therapeutic products.

Another key feature of Cilofexor is its strong market potential. As a novel drug candidate, there is significant potential for Cilofexor to make a big impact on the NASH market. The drug directly addresses one of the key drivers of NASH – an accumulation of fat in the liver – and has been shown to have positive results in early clinical trials. As research into Cilofexor continues, it is likely that demand for the drug will increase. Merchants who invest in Cilofexor now are well positioned to benefit from this trend.

Additionally, Cilofexor has several unique selling points that set it apart from other drugs in development for NASH. Its selectivity and potency make it an attractive option for patients and healthcare professionals alike. The drug's oral administration route is also highly desirable, as it is easy to administer and convenient for patients. The low incidence of side effects also bolsters the drug's potential.

In conclusion, Cilofexor is a highly promising drug candidate for the treatment of NASH. Its novel mechanism of action, good safety profile, and unique selling points make it an attractive product for merchants operating in this space. As the prevalence of NASH continues to climb, the demand for effective treatments will only increase. Those who invest in Cilofexor now will be well positioned to capitalize on this growing market and help deliver innovative and effective treatment options to patients suffering from this debilitating disease.

Chemical Structure: Cilofexor

CAS No.: 1418274-28-8

 

Cilofexor(GS-9674; GS9674;PX-104)

Catalog No.: YL-588 Only Used For Lab.

Cilofexor (GS-9674, GS9674, PX-104) is novel specific, non-steroidal farnesoid X receptor (FXR) agonist that reduces liver fibrosis and ameliorates portal hypertension in rat NASH models.

Biological Activity

Cilofexor (GS-9674, GS9674, PX-104) is a novel specific, non-steroidal farnesoid X receptor (FXR) agonist that reduces liver fibrosis and ameliorates portal hypertension in rat NASH models.
Steatohepatitis
Phase 2 Clinical

Physicochemical Properties

References

1. Gege C, et al. Curr Top Med Chem. 2014;14(19):2143-58.

URK-V588_COA

URK-V588_DataSheet

URK-V588_HNMR Report

URK-V588_LCMS Report

URK-V588_SDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• Our Nuclear Receptor/Transcription Factor Library products are used in a variety of industries, including pharmaceuticals, biotechnology, and agriculture.
• Most of our team are professionals with years of experience in research, production, management, and sales, so they have a clear division of labor and high work efficiency.
• We are committed to providing our customers with top-quality products and excellent service.
• By continuously optimizing corporate governance and enhancing Cilofexor CAS No.: 1418274-28-8 and service innovation, we promote harmonious and win-win corporate development and stakeholder cooperation.
• We are proud to serve as a trusted partner to leading scientists and researchers around the world.
• We insist on quality and inspect 100% of every finished product detail to ensure the performance of our Cilofexor CAS No.: 1418274-28-8.
• We understand that our customers have a choice when it comes to purchasing scientific research products, which is why we strive to be the best.
• With our professional team and top technology, we make our products perfect and beautiful and strive to be recognized by every customer.
• We are a Chinese factory that produces high-quality Nuclear Receptor/Transcription Factor Library products and provides professional services.
• We establish various cultural activities such as arts, sports, entertainment and leisure clubs on a long-term basis, and conduct activities on a regular or irregular basis to strengthen internal interpersonal communication and interaction, promote understanding and friendship, and enhance internal identity and cohesion.

Hot Tags: cilofexor cas no.: 1418274-28-8, China cilofexor cas no.: 1418274-28-8, epigenetic library for epigenetic analysis of epigenetic drug target validation, agonists for antibody therapy, epigenetic library for epigenetic regulation of cell adhesion, epigenetic library for epigenetic regulation of gene expression, epigenetic library for epigenetic analysis of epigenetic phenotype, inhibitors for neurodegenerative diseases